Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Stem Cell Therapy Offers a Possible Safe and Promising Alternative Approach for Treating Vitiligo: A Review

Author(s): Diana Esquivel, Rangnath Mishra and Anand Srivastava*

Volume 26, Issue 37, 2020

Page: [4815 - 4821] Pages: 7

DOI: 10.2174/1381612826666200730221446

Price: $65

Abstract

Background: Normal skin pigmentation pattern is an extremely important component of the appearance of a person, as it can be a significant factor in the social context of any person. A condition known as vitiligo is caused by the death of melanocytes leading to pigmentation loss in the skin. This affects all races across the globe and sometimes leads to social avoidance as in some communities, it is stigmatized. Although there are different pathobiological processes suspected because of the different underlying causes of vitiligo, autoimmunity and oxidative stress are suspected to be the most probable ones.

Objective: In this review, we present an overview of the underlying mechanisms causing and developing the disease. Also, some of the most successful treatments along with the clinical applications of Mesenchymal Stem Cells (MSCs) as a comprehensive approach for treating this condition will be covered.

Results: Autoreactive CD8+ T-cells are the primary suspect considered to be responsible for the destruction of melanocytes. Therefore, topical use of autoimmune inhibitors including those derived from MSCs, thanks to their immune-modulatory properties, have been reported to be successful in the promotion of repigmentation. MSCs can suppress the proliferation of CD8+T via the NKG2D pathway while inducing T-cell apoptosis. The use of pharmacological agents for reducing cellular oxidative stress with the help of topical application of antioxidants and growth factors also have been in use. Intravenous administration of MSCs has been shown to regulate the level of reactive oxidative species (ROS) in a mice model. Growth factors derived from platelet-rich-plasma (PRP) or from MSCs caused rapid tissue regeneration.

Conclusions: Finally, MSC therapy also has been shown to stimulate the mobilization of healthy melanocytes, leading to successful repigmentation of skin lesions in vitiligo patients.

Keywords: Melanocytes, mesenchymal stem cells, skin disease, stem cells therapy, vitiligo, immuno-modulation.

« Previous Next »
[1]
Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51(1): 52-61.
[http://dx.doi.org/10.1016/j.jaad.2003.12.031 ] [PMID: 15243524]
[2]
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61(3): 411-20.
[http://dx.doi.org/10.1016/j.jaad.2009.03.022 ] [PMID: 19577331]
[3]
Mosher D, Fitzpatrick T, Hori Y, Ortonne J. Disorders of melanocytes.Dermatology in general medicine. 4th ed. 903-95..
[4]
Taïeb A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 2000; 13(Suppl. 8): 41-7.
[http://dx.doi.org/10.1034/j.1600-0749.13.s8.9.x ] [PMID: 11041356]
[5]
Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008; 17(2): 139-40.
[http://dx.doi.org/10.1111/j.1600-0625.2007.00666.x ] [PMID: 18205713]
[6]
Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev 2016; 269(1): 11-25.
[http://dx.doi.org/10.1111/imr.12369 ] [PMID: 26683142]
[7]
Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol 2015; 135(4): 1080-8.
[http://dx.doi.org/10.1038/jid.2014.529 ] [PMID: 25521459]
[8]
Gilhar A, Pillar T, Eidelman S, Etzioni A. Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice. Arch Dermatol 1989; 125(10): 1363-6.
[http://dx.doi.org/10.1001/archderm.1989.01670220059008 ] [PMID: 2508572]
[9]
Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taïeb A. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003; 148(1): 95-101.
[http://dx.doi.org/10.1046/j.1365-2133.2003.05024.x ] [PMID: 12534601]
[10]
Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2(4): 145-53.
[http://dx.doi.org/10.1111/j.1600-0625.1993.tb00023.x ] [PMID: 8162332]
[11]
Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006; 24(4): 150-4.
[http://dx.doi.org/10.1016/j.tibtech.2006.01.010 ] [PMID: 16488036]
[12]
Hasegawa T, Ikeda S. Mesenchymal Stem Cells for the Treatment of Skin Diseases. AIMS Cell Tissue Eng 2017; 1: 104-17.
[http://dx.doi.org/10.3934/celltissue.2017.2.104]
[13]
Bertolini F, Lohsiriwat V, Petit J-Y, Kolonin MG. Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons. Biochim Biophys Acta 2012; 1826(1): 209-14.
[PMID: 22546620]
[14]
Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther 2018; 9(1): 63.
[http://dx.doi.org/10.1186/s13287-018-0791-7 ] [PMID: 29523213]
[15]
Aydemir I, Öztürk Ş, Kılıçaslan Sönmez P, Tuğlu Mİ. Mesenchymal stem cells in skin wound healing. Anatomy 2016; 10: 228-34.
[http://dx.doi.org/10.2399/ana.16.043]
[16]
Ghieh F, Jurjus R, Ibrahim A, et al. The Use of Stem Cells in Burn Wound Healing: A Review. BioMed Res Int 2015. 2015684084
[http://dx.doi.org/10.1155/2015/684084 ] [PMID: 26236731]
[17]
Zarei F, Soleimaninejad M. Role of growth factors and biomaterials in wound healing Artif Cells Nanomed Biotechnol 2018; 46(sup1)(Suppl 1): 906-11
[http://dx.doi.org/10.1080/21691401.2018.1439836] [PMID: 29448839]
[18]
van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129(9): 2220-32.
[http://dx.doi.org/10.1038/jid.2009.32 ] [PMID: 19242513]
[19]
Zhou MN, Zhang ZQ, Wu JL, et al. Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients’ autologous melanocytes transplantation efficiency. PLoS One 2013; 8(4) e60254
[http://dx.doi.org/10.1371/journal.pone.0060254 ] [PMID: 23577097]
[20]
Dogra S, Vinay K. Stem cells in vitiligo: Current position and prospects. Pigment Int 2014; 1: 8.
[http://dx.doi.org/10.4103/2349-5847.135430]
[21]
Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, et al. CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo Sci Transl Med 2014; 6: 223ra23-3..
[http://dx.doi.org/10.1126/scitranslmed.3007811]
[22]
Bishnoi A, Parsad D. Clinical and Molecular Aspects of Vitiligo Treatments. IJMS 1509; 19(5): 1509.
[23]
Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 2012; 132(7): 1869-76.
[http://dx.doi.org/10.1038/jid.2011.463 ] [PMID: 22297636]
[24]
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186(7): 4234-43.
[http://dx.doi.org/10.4049/jimmunol.1003668 ] [PMID: 21383241]
[25]
Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol 2015; 151(10): 1110-2.
[http://dx.doi.org/10.1001/jamadermatol.2015.1520 ] [PMID: 26107994]
[26]
Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatol Clin 2017; 35(2): 163-70.
[http://dx.doi.org/10.1016/j.det.2016.11.007 ] [PMID: 28317526]
[27]
Lan C-CE, Chen G-S, Chiou M-H, Wu C-S, Chang C-H, Yu H-S. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153(3): 498-505.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06739.x ] [PMID: 16120133]
[28]
Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of Human Mesenchymal Stem Cells with Alloantigen-Induced T Lymphocyte Activation Favors the Differentiation of CD4+ T Cell Subsets Expressing CD25 and/or CTLA4 Molecules. Hematologica 2004; 104: 2123-3.
[http://dx.doi.org/10.1182/blood.V104.11.2123.2123]
[29]
Li M, Sun X, Kuang X, Liao Y, Li H, Luo D. Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β. Clin Exp Immunol 2014; 178(3): 516-24.
[http://dx.doi.org/10.1111/cei.12423 ] [PMID: 25070361]
[30]
Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol 2019; 10: 1191.
[http://dx.doi.org/10.3389/fimmu.2019.01191 ] [PMID: 31214172]
[31]
Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10(5): 544-55.
[http://dx.doi.org/10.1016/j.stem.2012.03.007 ] [PMID: 22542159]
[32]
Kim DS, Jang IK, Lee MW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-ƴ. EBioMedicine 2018; 28: 261-73.
[http://dx.doi.org/10.1016/j.ebiom.2018.01.002 ] [PMID: 29366627]
[33]
Zhang S, Yi X, Su X, et al. Ginkgo biloba extract protects human melanocytes from H2 O2 -induced oxidative stress by activating Nrf2. J Cell Mol Med 2019; 23(8): 5193-9.
[http://dx.doi.org/10.1111/jcmm.14393 ] [PMID: 31148371]
[34]
Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol 1999; 12(3): 132-8.
[http://dx.doi.org/10.1159/000029867 ] [PMID: 10393521]
[35]
Denu RA, Hematti P. Effects of Oxidative Stress on Mesenchymal Stem Cell Biology. Oxid Med Cell Longev 2016. 20162989076
[http://dx.doi.org/10.1155/2016/2989076 ] [PMID: 27413419]
[36]
Valle-Prieto A, Conget PA. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells Dev 2010; 19(12): 1885-93.
[http://dx.doi.org/10.1089/scd.2010.0093 ] [PMID: 20380515]
[37]
Kim Y, Jo SH, Kim WH, Kweon O-K. Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury. Stem Cell Res Ther 2015; 6: 229.
[http://dx.doi.org/10.1186/s13287-015-0236-5 ] [PMID: 26612085]
[38]
da Costa Gonçalves F, Grings M, Nunes NS, et al. Antioxidant properties of mesenchymal stem cells against oxidative stress in a murine model of colitis. Biotechnol Lett 2017; 39(4): 613-22.
[http://dx.doi.org/10.1007/s10529-016-2272-3 ] [PMID: 28032203]
[39]
Lanza C, Morando S, Voci A, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009; 110(5): 1674-84.
[http://dx.doi.org/10.1111/j.1471-4159.2009.06268.x ] [PMID: 19619133]
[40]
Zhu L, Lin X, Zhi L, et al. Mesenchymal stem cells promote human melanocytes proliferation and resistance to apoptosis through PTEN pathway in vitiligo. Stem Cell Res Ther 2020; 11(1): 26.
[http://dx.doi.org/10.1186/s13287-019-1543-z ] [PMID: 31941556]
[41]
Zhang F, Peng W, Zhang J, et al. New strategy of bone marrow mesenchymal stem cells against oxidative stress injury via Nrf2 pathway: oxidative stress preconditioning. J Cell Biochem 2019; 120(12): 19902-14.
[http://dx.doi.org/10.1002/jcb.29298 ] [PMID: 31347718]
[42]
Bellei B, Migliano E, Tedesco M, et al. Adipose tissue-derived extracellular fraction characterization: biological and clinical considerations in regenerative medicine. Stem Cell Res Ther 2018; 9(1): 207.
[http://dx.doi.org/10.1186/s13287-018-0956-4 ] [PMID: 30092820]
[43]
Owczarczyk-Saczonek A, Wociór A, Placek W, Maksymowicz W, Wojtkiewicz J. The Use of Adipose-Derived Stem Cells in Selected Skin Diseases (Vitiligo, Alopecia, and Nonhealing Wounds). Stem Cells Int 2017. 20174740709
[http://dx.doi.org/10.1155/2017/4740709 ] [PMID: 28904532]
[44]
Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res 2009; 22(1): 42-65.
[http://dx.doi.org/10.1111/j.1755-148X.2008.00528.x ] [PMID: 19040503]
[45]
Lim W-S, Kim C-H, Kim J-Y, Do B-R, Kim EJ, Lee A-Y. Adipose-derived stem cells improve efficacy of melanocyte transplantation in animal skin. Biomol Ther (Seoul) 2014; 22(4): 328-33.
[http://dx.doi.org/10.4062/biomolther.2014.065 ] [PMID: 25143812]
[46]
Khanna U, Khandpur S. What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo? Indian Dermatol Online J 2019; 10(3): 234-43.
[http://dx.doi.org/10.4103/idoj.IDOJ_310_18 ] [PMID: 31149564]
[47]
Wu C-S, Yu C-L, Wu C-S, Lan C-CE, Yu H-S. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 2004; 13(12): 755-63.
[http://dx.doi.org/10.1111/j.0906-6705.2004.00221.x ] [PMID: 15560759]
[48]
Smith MP, Ly K, Thibodeaux Q, Bhutani T, Nakamura M. Home phototherapy for patients with vitiligo: challenges and solutions. Clin Cosmet Investig Dermatol 2019; 12: 451-9.
[http://dx.doi.org/10.2147/CCID.S185798 ] [PMID: 31388308]
[49]
Sanford JA, Gallo RL. Functions of the skin microbiota in health and disease. Semin Immunol 2013; 25(5): 370-7.
[http://dx.doi.org/10.1016/j.smim.2013.09.005 ] [PMID: 24268438]
[50]
Catinean A, Neag MA, Mitre AO, Bocsan CI, Buzoianu AD. Microbiota and Immune-Mediated Skin Diseases-An Overview. Microorganisms 2019; 7(9): 279.
[http://dx.doi.org/10.3390/microorganisms7090279 ] [PMID: 31438634]
[51]
Ganju P, Nagpal S, Mohammed MH, et al. Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects. Sci Rep 2016; 6: 18761.
[http://dx.doi.org/10.1038/srep18761 ] [PMID: 26758568]
[52]
Nagashima K, Sawa S, Nitta T, et al. Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat Immunol 2017; 18(6): 675-82.
[http://dx.doi.org/10.1038/ni.3732 ] [PMID: 28436956]
[53]
Dong X, Feng X, Liu J, et al. Characteristics of Intestinal Microecology during Mesenchymal Stem Cell-Based Therapy for Mouse Acute Liver Injury. Stem Cells Int 2019. 20192403793
[http://dx.doi.org/10.1155/2019/2403793 ] [PMID: 30867666]

Rights & Permissions Print Cite
Article Metrics
70
6
© 2024 Bentham Science Publishers | Privacy Policy